Assessing the Acceptability of Home Blood Monitoring for Patients With Cancer Who Are Receiving Systemic Anticancer Therapy From a Patient, Caregiver, and Clinician Perspective: Focus Group and Interview Study.

All participants came from one UK NHS cancer centre, so views may not apply to other centres or countries. Participants were selected through clinical teams and had to agree to take part, so they may have been more open to home monitoring than patients who would decline. The study explored perceptions of a prototype and its concept; it did not test whether home blood monitoring is safe, accurate, acceptable in routine use, or changes treatment delays. Recruitment was affected by the pandemic, and after March 2020 only remote interviews were done, with no further caregivers invited. The patient sample was mostly women and mostly breast cancer, and none were older than 70 years, despite concerns about older and more disabled users. All participants had internet access, so the study did not capture the experiences of people without internet or with limited digital access. The device development team helped conduct interviews, although analysis was done by researchers outside that team.

Do not read this as evidence that home blood monitoring improves cancer care or is ready for routine use. The study reports perceptions of a prototype concept, not clinical outcomes, accuracy, safety, or treatment delays.